Effect of Resveratrol in controlling blood glucose in type 2 Diabetic patients

Effect of resveratrol in cotrolling the fasting blood glucose in patients with type 2 DM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201111198129N1

Enrollment

Registered

2012-11-11

Start date

2012-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non- Insulin Dependent Diabetes mellitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group(500 mg / twice daily of Resveratrol capsules )

morning and evening

consumed orally and for a period of 45 days. Intervention 2: Intervention group(500 mg / twice daily of Plasibo capsules )

consumed orally and for a period of 45 days.

Treatment - Drugs

Intervention group(500 mg / twice daily of Resveratrol capsules )

Intervention group(500 mg / twice daily of Plasibo capsules )

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Iinclusion Criteria: Patients with T2DM; subjects with good peripheral vain; patients on oral hypoglycemic treatment (met.formine.and/or glibenclamid) as long as they are on stable doses and the dosage is not changed during the course of the study. Exclusion Criteria: Subjects on any antioxidant therapy such as vitamin supplements ; having allergy to grapes,green tea and peanuts; patients with type 1 diabetes; pregnant women ; lactating mothers; severe heart disease ; hepatic disease ; renal dysfunction ; smoking.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HbA1c. Timepoint: Before the intervention and 45 days after intervention, three months after the end of the intervention. Method of measurement: boronate affinity assay kit (Nycocard HbA1c, Axis- SHIELD poc AS, Norway).;Insuline. Timepoint: Before the intervention and 45 days after intervention, three months after the end of the intervention. Method of measurement: electrochemiluminescence immunoassay "ECLIA" kit, (Elecsys and Cobbas, Roche Diagnostics Gmbh, Sandhofer strasse 116, D – 68305 mannheim.;FBS. Timepoint: Before the intervention and 45 days after intervention, three months after the end of the intervention. Method of measurement: by enzymatic method.	—

Measure

Time frame

HbA1c. Timepoint: Before the intervention and 45 days after intervention, three months after the end of the intervention. Method of measurement: boronate affinity assay kit (Nycocard HbA1c, Axis- SHIELD poc AS, Norway).;Insuline. Timepoint: Before the intervention and 45 days after intervention, three months after the end of the intervention. Method of measurement: electrochemiluminescence immunoassay "ECLIA" kit, (Elecsys and Cobbas, Roche Diagnostics Gmbh, Sandhofer strasse 116, D – 68305 mannheim.;FBS. Timepoint: Before the intervention and 45 days after intervention, three months after the end of the intervention. Method of measurement: by enzymatic method.

—

Secondary

Measure	Time frame
Cholestrol. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: by enzymatic method,in mg/dl.;Triglyceride. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: by enzymatic method,in mg/dl.;HDL-cholestrole. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: by enzymatic method,in mg/dl.;LDL-cholestrole. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: by enzymatic method,in mg/dl.;Blood pressure. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: using a standard mercury sphygmomanometer.	—

Measure

Time frame

Cholestrol. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: by enzymatic method,in mg/dl.;Triglyceride. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: by enzymatic method,in mg/dl.;HDL-cholestrole. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: by enzymatic method,in mg/dl.;LDL-cholestrole. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: by enzymatic method,in mg/dl.;Blood pressure. Timepoint: before the intervention and after 45 days of intervention. Method of measurement: using a standard mercury sphygmomanometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Movahed

Bushehr university of medical sciences

amirali_1957@yahoo.comamovahed58@gmail.com+98 77 1252 9198

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026